Mainland China

AMTD Int’l Proposes for Name Change to “AMTD IDEA” and Announces Its New Ticker to Be “AMTD”

Retrieved on: 
Thursday, January 20, 2022 - 9:23pm

The Company proposes to change its name from AMTD International Inc. to AMTD IDEA Group subject to approval by vote at the EGM.

Key Points: 
  • The Company proposes to change its name from AMTD International Inc. to AMTD IDEA Group subject to approval by vote at the EGM.
  • The Company also announced that the ticker symbol for the Companys ADSs will be changed to AMTD effective on January 31, 2022.
  • The proposed name change will not affect any rights of shareholders or the Companys operations and financial position.
  • Statements that are not historical facts, including statements about AMTD Internationals beliefs, plans, and expectations, are forward-looking statements.

15th Asian Financial Forum attracts 63,000+ views

Retrieved on: 
Wednesday, January 12, 2022 - 10:00am

As of 11 January, the AFF virtual platform had seen more than 63,000 views from 80 countries and regions.

Key Points: 
  • As of 11 January, the AFF virtual platform had seen more than 63,000 views from 80 countries and regions.
  • Jean-Claude Trichet, Former President, European Central Bank, offered his views on how the financial industry, regulators and policymakers should step up their concerted efforts in addressing key issues related to monetary stability in times of uncertainty.
  • Delivering his remarks on the second morning of AFF 2022, Paul Chan, Financial Secretary of the HKSAR, noted the tremendous opportunities for Hong Kong's financial market created by Mainland China's continued development.
  • PwC and the HKTDC jointly presented a pulse survey, "ESG Investing: Challenges and Opportunities for Hong Kong", during AFF 2022.

Cipia Announces First Purchase Order from Technomous and Start of Production with China's Largest Automaker SAIC Motor

Retrieved on: 
Friday, December 31, 2021 - 3:27pm

TEL AVIV, Israel, Dec. 30, 2021 /PRNewswire/ -- Cipia (TASE: CPIA), an auto-tech company providing automakers and fleets with advanced AI based in-cabin sensing solutions for driver and interior monitoring, announces the first purchase order (PO) from Tier 1 Technomous, and start of production (SOP) with China's largest automotive company SAIC Motor.

Key Points: 
  • TEL AVIV, Israel, Dec. 30, 2021 /PRNewswire/ -- Cipia (TASE: CPIA), an auto-tech company providing automakers and fleets with advanced AI based in-cabin sensing solutions for driver and interior monitoring, announces the first purchase order (PO) from Tier 1 Technomous, and start of production (SOP) with China's largest automotive company SAIC Motor.
  • David Tolub, CEO of Cipia said: "We are delighted to partner with Technomous and SAIC Motor, and begin the serial production of a vehicle which integrated Cipia's Driver Senseless than a year after kickoff.
  • The project with Technomous for SAIC was included in Cipia's IPO prospectus as part of the design wins and forecasted lifecycle value.
  • Cipia is constantly pushing the boundaries of what intelligent sensing solutions can see and accomplish, for better and safer mobility.

Cipia Announces First Purchase Order from Technomous and Start of Production with China's Largest Automaker SAIC Motor

Retrieved on: 
Thursday, December 30, 2021 - 2:00pm

TEL AVIV, Israel, Dec. 30, 2021 /PRNewswire/ -- Cipia (TASE: CPIA), an auto-tech company providing automakers and fleets with advanced AI based in-cabin sensing solutions for driver and interior monitoring, announces the first purchase order (PO) from Tier 1 Technomous, and start of production (SOP) with China's largest automotive company SAIC Motor.

Key Points: 
  • TEL AVIV, Israel, Dec. 30, 2021 /PRNewswire/ -- Cipia (TASE: CPIA), an auto-tech company providing automakers and fleets with advanced AI based in-cabin sensing solutions for driver and interior monitoring, announces the first purchase order (PO) from Tier 1 Technomous, and start of production (SOP) with China's largest automotive company SAIC Motor.
  • David Tolub, CEO of Cipia said: "We are delighted to partner with Technomous and SAIC Motor, and begin the serial production of a vehicle which integrated Cipia's Driver Senseless than a year after kickoff.
  • The project with Technomous for SAIC was included in Cipia's IPO prospectus as part of the design wins and forecasted lifecycle value.
  • Cipia is constantly pushing the boundaries of what intelligent sensing solutions can see and accomplish, for better and safer mobility.

Aerogen Pharma Enters into Exclusive Agreements with Nuance Pharma to Advance Treatment of Respiratory Distress Syndrome in Premature Infants in China

Retrieved on: 
Wednesday, December 22, 2021 - 11:44pm

The neonatology community has long hoped for a non-invasive alternative that will enable the benefits of surfactant treatment without these drawbacks.

Key Points: 
  • The neonatology community has long hoped for a non-invasive alternative that will enable the benefits of surfactant treatment without these drawbacks.
  • Colin Telfer, Head of Business Operations at Aerogen Pharma, added: "Non-invasive delivery of surfactant to infants with RDS represents both a huge unmet medical need and a compelling commercial opportunity for Aerogen Pharma.
  • We are delighted to be partnering with Nuance to develop and commercialize AeroFact in China, which today stands as the world's largest surfactant market."
  • Nuance is a Shanghai headquartered specialty care focused biopharma company focusing on respiratory, pain management and iron deficiency areas.

KPMG report highlights fintech and digitalisation as growth drivers of Mainland China's securities industry

Retrieved on: 
Monday, August 30, 2021 - 5:20am

HONG KONG, Aug 30, 2021 - (ACN Newswire) - Capital market reforms are presenting opportunities for Mainland China's securities industry, with companies that embrace fintech and digitalisation best positioned for long-term growth, according to KPMG analysis.

Key Points: 
  • HONG KONG, Aug 30, 2021 - (ACN Newswire) - Capital market reforms are presenting opportunities for Mainland China's securities industry, with companies that embrace fintech and digitalisation best positioned for long-term growth, according to KPMG analysis.
  • The 15th annual Mainland China Securities Survey analyses the industry based on the 2020 financial statements of 137 securities companies in mainland China.
  • The report highlights the need for the securities industry to drive transformation by creating a customer-oriented ecosystem with other players in the capital market."
  • Tony Cheung, Head of Financial Services, KPMG China, says: "Fintech and digitalisation will be the core drivers of growth for the next strategic cycle.

Promega and Henlius Developing Microsatellite Instability Companion Diagnostic IVD Kit for Serplulimab in China

Retrieved on: 
Thursday, August 5, 2021 - 11:00am

Shanghai Promega Biological Products Co., Ltd. and Shanghai Henlius Biotech, Inc. will develop and commercialize a microsatellite instability (MSI) companion diagnostic IVD kit to identify cancer patients likely to benefit from serplulimab, a novel anti-PD-1 monoclonal antibody (mAb) developed by Henlius for the potential treatment of microsatellite instability-high (MSI-H) solid tumors.

Key Points: 
  • Shanghai Promega Biological Products Co., Ltd. and Shanghai Henlius Biotech, Inc. will develop and commercialize a microsatellite instability (MSI) companion diagnostic IVD kit to identify cancer patients likely to benefit from serplulimab, a novel anti-PD-1 monoclonal antibody (mAb) developed by Henlius for the potential treatment of microsatellite instability-high (MSI-H) solid tumors.
  • The kit will be available to doctors in the Chinese Mainland to screen for MSI and inform immunotherapy options.
  • The New Drug Application (NDA) of serplulimab was recently granted priority review by the National Medical Products Administration (NMPA) in China.
  • Promega has received innovation status and priority review by the NMPA in China and also intends to seek regulatory clearance for a Promega MSI IVD in China.

ImmuneOncia and 3D Medicines Signed Exclusive License Agreement to Develop, Manufacture and Commercialize IMC-002 in Greater China

Retrieved on: 
Wednesday, March 31, 2021 - 2:00am

The agreement includes uses of IMC-002 for oncology indication as a monotherapy or combination agent in the Territory of Greater China (Mainland China, Hong Kong, Macau, and Taiwan).

Key Points: 
  • The agreement includes uses of IMC-002 for oncology indication as a monotherapy or combination agent in the Territory of Greater China (Mainland China, Hong Kong, Macau, and Taiwan).
  • Under the terms of the agreement, ImmuneOncia will receive an upfront payment of $8 million from 3D Medicines.
  • In exchange, 3D Medicines will receive rights to develop, manufacture and commercialize IMC-002 in Greater China.
  • "We are very pleased to enter into this exclusive collaboration with ImmuneOncia" said John Gong, M.D., Ph.D., Chairman and Chief Executive Officer of 3D Medicines.

Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China

Retrieved on: 
Thursday, February 25, 2021 - 9:07pm

The amended agreement extends Pierre Fabres commercial rights for NERLYNX to Greater China, which includes mainland China, Taiwan, Hong Kong and Macau.

Key Points: 
  • The amended agreement extends Pierre Fabres commercial rights for NERLYNX to Greater China, which includes mainland China, Taiwan, Hong Kong and Macau.
  • Concomitantly, Puma and CANbridge Pharmaceuticals, Inc., a biopharmaceutical company focused on developing drug candidates in China and North Asia, have mutually agreed to terminate the license agreement to commercialize NERLYNX (neratinib) in Greater China.
  • Alan H. Auerbach, Chief Executive Officer and President of Puma, said, We are pleased to extend our collaboration with Pierre Fabre into the Greater China region.
  • Pierre Fabre is well equipped with existing infrastructure to make NERLYNX a success in mainland China and Pierre Fabre plans to make NERLYNX available to breast cancer patients in mainland China in the second quarter of this year.

Trendy Lifestyle Products take their Cue from Big Data

Retrieved on: 
Monday, December 7, 2020 - 10:00am

Jason Tjiptadi, Research Analyst at Euromonitor International, provided his perspective on the current state of the industry through data analysis.

Key Points: 
  • Jason Tjiptadi, Research Analyst at Euromonitor International, provided his perspective on the current state of the industry through data analysis.
  • He pointed out that in regions such as Mainland China, India and Indonesia, millennials are now high-income earners who are willing to spend on quality products.
  • He said that ViuTV and Netflix are two of the media channels that have emerged rapidly among kids in Hong Kong.
  • With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub.